Summary of patient and ocular characteristics in systematic review
| Patient characteristics | No of patients (n=14) | % |
| Age (years) | ||
| <50 | 2 | 14.3 |
| 50–59 | 4 | 28.5 |
| 60–69 | 4 | 28.5 |
| 70–79 | 3 | 21.4 |
| >80 | 1 | 7.1 |
| Sex | ||
| Male | 7 | 50.0 |
| Female | 7 | 50.0 |
| Immunotherapy | ||
| Nivolumab | 5 | 35.7 |
| Pembrolizumab | 3 | 21.4 |
| Ipilimumab | 2 | 14.3 |
| Ipilimumab+Nivolumab | 3 | 21.4 |
| Ipilimumab+pembrolizumab | 1 | 7.1 |
| Presenting symptom(s) | ||
| Blurred vision | 6 | 42.9 |
| Unspecified vision loss | 5 | 35.7 |
| Photopsia | 5 | 35.7 |
| Photophobia | 2 | 14.3 |
| Metamorphopsia | 1 | 7.1 |
| Nyctalopia | 1 | 7.1 |
| Visual field deficit | 1 | 7.1 |
| Bilateral involvement | 14 | 100.0 |
| Anti-retinal antibodies | ||
| Present | 1 | 7.1 |
| Not tested | 13 | 92.9 |
| Systemic irAEs | ||
| Sarcoid-like granulomatous reaction | 2 | 14.3 |
| Autoimmune hepatitis/transaminitis | 2 | 14.3 |
| Autoimmune thyroiditis | 1 | 7.1 |
| Adrenal insufficiency | 1 | 7.1 |
| Pruritus | 1 | 7.1 |
| None | 1 | 7.1 |
| Not reported | 7 | 50.0 |
| Cessation of immunotherapy | ||
| Yes | 10 | 71.4 |
| No | 2 | 14.3 |
| Not reported | 2 | 14.3 |
| Systemic melanoma status | ||
| Partial response | 2 | 14.3 |
| Progression of disease | 3 | 21.4 |
| Not reported | 9 | 64.3 |
| Ocular characteristics | No of eyes (n=28) | % |
| BCVA at presentation | ||
| 6/4.8 to <6/12 | 11 | 39.3 |
| 6/12 to <6/30 | 10 | 35.7 |
| 6/30 to 3/60 | 5 | 17.9 |
| >3/60 | 2 | 7.1 |
| Retinal findings | ||
| Melanoma-associated retinopathy (MAR) | 4 | 14.3 |
| Acute exudative polymorphous vitelliform maculopathy (AEPVM) | 12 | 42.9 |
| Serous retinal detachment | 10 | 35.7 |
| Birdshot-like chorioretinopathy | 2 | 7.1 |
| Concurrent optic nerve involvement | 2 | 7.1 |
| Concurrent choroidal detachment | 4 | 14.3 |
| Concurrent choroidal neovascularisation (CNV) | 1 | 3.6 |
| Treatment | ||
| Topical corticosteroids | 10 | 35.7 |
| Periocular corticosteroids | 5 | 17.9 |
| Intravitreal corticosteroids | 4 | 14.3 |
| Systemic corticosteroids | 16 | 57.1 |
| Other systemic immunosuppressants | 2 | 7.1 |
| Ocular outcome | ||
| Complete resolution | 11 | 39.3 |
| Partial resolution | 10 | 35.7 |
| No change | 4 | 14.3 |
| Further visual decline | 1 | 3.6 |
| No follow-up | 2 | 7.1 |
| Symptom onset after immunotherapy initiation (weeks) | ||
| Median (IQR) | 7.5 (5.25–19.75) | |
| Duration of follow-up (weeks) | ||
| Median (IQR) | 17 (4.75–26) | |